<DOC>
	<DOCNO>NCT02181985</DOCNO>
	<brief_summary>The objective ASSENT 3 evaluate safety efficacy full dose tenecteplase heparin sodium ( group A ) , full dose tenecteplase combine enoxaparin ( group B ) half dose tenecteplase combine abciximab heparin sodium ( group C ) .</brief_summary>
	<brief_title>Full Dose Tenecteplase ( TNK-tPA ) Together With Heparin Sodium , Full Dose Tenecteplase With Enoxaparin , Half Dose Tenecteplase Together With Abciximab Heparin Sodium Patients With Acute Myocardial Infarction ( AMI )</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Abciximab</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Immunoglobulin Fab Fragments</mesh_term>
	<mesh_term>Tenecteplase</mesh_term>
	<mesh_term>Tissue Plasminogen Activator</mesh_term>
	<criteria>Onset symptom AMI within six hour prior randomisation A twelvelead electrocardiogram one following : STsegment elevation ≥ 0.1 millivolt ( mV ) two limb lead , ≥ 0.2 mV two contiguous precordial lead indicative AMI , leave bundlebranch block Age ≥ 18 Informed consent receive Hypertension define blood pressure &gt; 180/110 mm Hg ( systolic BP &gt; 180 mm Hg and/or diastolic BP &gt; 110 mm Hg ) repeat measurement current admission prior randomization Use abciximab ( ReoPro ® ) glycoproteinIIb/IIIa antagonist within precede 7 day Major surgery , biopsy parenchymal organ , significant trauma within 2 month Any minor head trauma trauma occur onset current myocardial infarction Any known history stroke transient ischemic attack dementia Any known structural damage central nervous system Prolonged cardiopulmonary resuscitation ( &gt; 10 minute ) previous two week Current oral anticoagulation Standard unfractionated heparin ( heparin sodium ) &gt; 5000 IU subcutaneous dose within 6 hour randomization therapeutic dose low molecular weight heparin Known thrombocytopenia ( prior platelet count 100000 cells/μl ( 100 x10**9/l ) ) Known renal insufficiency ( prior Screatinine &gt; 2.5 mg % ( &gt; 220 μmol/l ) men &gt; 2.0 mg % ( &gt; 175 μmol/l ) ) woman Pregnancy lactation , parturition within previous 30 day . Women childbearing potential must negative pregnancy test , use medically accept method birth control Treatment investigational drug another study protocol past 7 day Previous enrollment study Known sensitivity TNKtPA , tPA , abciximab , heparin low molecular weight heparin Any condition investigator feel would place patient increase risk investigational therapy initiate Inability follow protocol comply followup requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>